Skip to content

The Sunnybrook Type 2 Diabetes Study

The Sunnybrook Type 2 Diabetes Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04455867
Acronym
S2DS
Enrollment
500
Registered
2020-07-02
Start date
2017-12-21
Completion date
2026-12-31
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PreDiabetes, Type 2 Diabetes

Keywords

Mood, Cognition, Brain Imaging, Type 2 Diabetes, Sleep, Exercise

Brief summary

The Sunnybrook Type 2 Diabetes Study (S2DS) is a prospective observational study of people with prediabetes or Type 2 Diabetes Mellitus (T2DM), that aims to understand the aetiologies, manifestations, and clinical consequences of mood and cognitive complications. The study recruits from the services at Sunnybrook Health Sciences Centre and from the neighbouring University Health Network Toronto Rehabilitation Institute Cardiac Rehabilitation Program.

Detailed description

The S2DS is a prospective observational study of people with prediabetes or T2DM recruited from Sunnybrook Health Sciences Centre and the neighbouring University Health Network Toronto Rehabilitation Institute Cardiac Rehabilitation Program. Participants recruited from Sunnybrook are receiving care from services there (e.g. Family Medicine, Endocrinology, and the Sunnybrook Diabetes Education Centre). Participants recruited from the Toronto Rehab are undertaking a 6-month stepped hybrid (home and clinic based) aerobic plus resistance exercise intervention as part of a program at that site (e.g. the Diabetes, Exercise, and Healthy Lifestyle Program). Study assessments are conducted at baseline, 3 months, 6 months and 18 months. Main outcomes include cognitive performance, assessed using a detailed neurocognitive battery, and mood symptoms assessed via research criteria for a depressive episode and self-report instruments. Other lifestyle factors are also examined, including physical activity, sleep quality, diet, and subjective stress. Diabetes complications and characteristics are monitored, as are all concomitant medications and supplements. With permission, participant data are linked prospectively to public health records to ascertain long-term outcomes and health services utilization. The cohort is characterized using biological, neuroimaging and biometric measures. Fasting morning blood and urine samples are taken at each assessment. Serum, plasma, whole blood, and white blood cells are bio-banked for biochemical, genetic and other analyses. The MRI study includes a 1.5 hr MRI scan at 3.0 T. Sequences performed include structural imaging (T1, T2, DTI and FLAIR) and resting state functional MRI. Two optional sub-studies are offered: a cerebrovascular reactivity MRI protocol, and a sleep quality and apnea protocol (baseline, 6 month and 18 month visits). The sleep study uses an overnight wearable sleep monitor.

Interventions

BEHAVIORALDiabetes Exercise and Healthy Lifestyle Program

The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.

Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education

Sponsors

University Health Network, Toronto
CollaboratorOTHER
University of Toronto
CollaboratorOTHER
Sunnybrook Health Sciences Centre
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have at least one of the following: high HbA1c, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), but not yet diagnosed with Type 2 diabetes or have a diagnosis of Type 2 diabetes. * Be able to communicate in English * Be 18 years of age or older

Exclusion criteria

* Pregnancy * Inability to give informed consent * Current cancer diagnosis * Have a prior diagnosis of bipolar disorder or schizophrenia. * Have a prior diagnosis of a neurological and/or neurodegenerative disorder. * Have a current substance use disorder or a previous substance use disorder diagnosed within the last 5 years (excluding nicotine) * Poor score on the Mini Mental State Examination (MMSE)

Design outcomes

Primary

MeasureTime frameDescription
Depressive episode6 MonthsDepressive episodes are identified using a Structured Clinical Interview for the DSM-5 criteria (SCID-5RV).
Neuropsychological function6 MonthsA Z-score computed from a sensitive neuropsychological battery is administered based on the Canadian Stroke Network & National Institutes of Neurological Disorders recommendations.

Secondary

MeasureTime frameDescription
Depressive symptomsBaseline, 3 Month, 6 Month, 18 MonthDepressive symptoms are monitored using the Beck Depression Inventory-II (BDI-II).
Cognitive StatusBaseline, 3 Month, 6 Month, 18 MonthCognitive status is monitored using the Montreal Cognitive Assessment (MoCA).

Countries

Canada

Contacts

Primary ContactWalter Swardfager, PhD
w.swardfager@utoronto.ca416-480-6100
Backup ContactChelsi Major-Orfao, MEd
chelsi.major-orfao@sri.utoronto.ca416-480-6100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026